A LinkedIn post from HistoSonics highlights the company’s planned presence at the AHPBA Annual Meeting in Miami Beach, with a focus on its Edison Histotripsy System and liver applications. The post describes an evening clinical forum on March 19 featuring surgical oncologist Young K. Hong, positioned as a peer-driven discussion for current and emerging histotripsy users.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The company’s LinkedIn communication suggests an emphasis on clinician engagement and education, which may support broader adoption of its histotripsy technology over time. For investors, increased visibility among hepatobiliary surgeons and the clarification that non-liver uses are currently limited to clinical investigations underscore both the near-term commercial focus and longer-term pipeline optionality.
The mention of booth availability for discussions around the Edison System at the exhibition floor indicates targeted outreach to a specialized clinical audience. If this engagement translates into growing clinical interest, procedure volumes, and additional clinical data, it could enhance HistoSonics’ competitive positioning within image-guided, noninvasive oncology treatment modalities.